Invivyd Announces PEMGARDA™ ( pemivibart ) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

3 weeks ago

WALTHAM, Mass., Aug. 27, 2024 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced positive 180-day exploratory clinical efficacy data from the company's ongoing CANOPY Phase 3 ...

Ticker	Sentiment	Impact
IVVD	Neutral	9 %